Is COX-2 expression a valuable independent prognostic factor in pancreatic cancer?

Apr 20, 2010

A research team from Czech Republic immunohistochemically examined the expression of cyclooxygenase-2 (COX-2) in pancreatic ductal adenocarcinoma using monoclonal and polyclonal antibodies to validate the potential usefulness of this marker in predictive oncology. Immunohistochemically assessed levels of COX-2 were not proven to represent a valuable independent prognostic factor and are not superior to the conventional prognostic factors.

Cyclooxygenase-2 (COX-2) represents a key modulatory molecule in inflammation and . COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer. In the literature, the prognostic significance of COX-2 expression including the role of antibody used for an evaluation of COX-2 expression profile have been discussed. A significant inverse relationship between COX-2 overexpression and survival rates has previously been reported in retrospective studies of different types of malignancies. Conflicting results have been shown in pancreatic cancer and the possible role of primary antibody used for the detection of COX-2 expression has been suggested.

A research article to be published on April 21, 2010 in the addresses this question.

The overexpression of COX-2 was demonstrated in a significant proportion of pancreatic ductal adenocarcinomas using both monoclonal and polyclonal antibodies and a relationship of COX-2 to the of pancreatic cancer was confirmed.

Using the monoclonal antibody, a significantly shorter disease free survival was found in patients with COX-2 positive tumors. No significant results were obtained with regard to overall survival. High histological grade and nodal involvement were associated with significantly shorter survival.

In conclusion, the level of COX-2 expression does not seem to be a valuable independent prognostic factor. Immunohistochemical assessment of COX-2 expression is not superior to the conventional prognostic factors such as grade, stage and nodal status.

Explore further: New cancer drug target involving lipid chemical messengers

More information: Hermanova M, Karasek P, Tomasek J, Lenz J, Jarkovsky J, Dite P. Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer. World J Gastroenterol 2010; 16(15): 1879-1884 www.wjgnet.com/1007-9327/full/v16/i15/1879.htm

add to favorites email to friend print save as pdf

Related Stories

COX-2 inhibitors delay pancreatic cancer precursors in mice

Aug 01, 2007

Nimesulide, a cyclooxygenase-2 (COX-2) inhibitor, delays the progression of precancerous pancreatic lesions in mice, according to researchers at David Geffen School of Medicine at UCLA. While inflammation has been shown to ...

Study: Celecoxib can cause arrhythmias

Jan 15, 2008

U.S. medical researchers have determined the anti-inflammatory drug celecoxib (Celebrex) can adversely affect heart rhythm in fruit fly and rat models.

Thyme oil can inhibit COX2 and suppress inflammation

Jan 13, 2010

For those who do not drink, researchers have found that six essential oils -from thyme, clove, rose, eucalyptus, fennel and bergamot—can suppress the inflammatory COX-2 enzyme, in a manner similar to resveratrol, the chemical ...

More fish oil, less vegetable oil, better for your health

Jul 26, 2007

Scientists have provided new evidence that using more fish oil than vegetable oil in the diet decreases the formation of chemicals called prostanoids, which, when produced in excess, increase inflammation in various tissues ...

Aspirin shows promise for colon cancer patients

Aug 11, 2009

Men and women who were diagnosed with colorectal cancer and began regular use of aspirin had a lower risk of overall and colorectal cancer death compared to patients not using aspirin, according to a study in the August 12 ...

Recommended for you

User comments : 0